The Women’s Health Collaboration Program is part of the MLSC’s Women’s Health Initiative. This program supports collaborative projects that aim to improve the discovery, technical innovation, and/or analysis of datasets to answer pressing life science questions around women’s health. It incentivizes translational projects that develop novel solutions to treat conditions that solely or disproportionately affect women or have a different presentation between genders.
Up to $5 million capital dollars are available for the current program round, with each award anticipated to be approximately $750,000 to support data generation and equipment at not-for-profit partners.
The application period will run from Oct. 3, 2022 to Jan. 12, 2023 at 8 p.m. EST.
Eligibility & Evaluation
Project teams are to be comprised of not-for-profit applicants collaborating with at least one for-profit Massachusetts life science company. All not-for-profit applicants must be a Massachusetts legal entity such as an academic/research institution, a hospital engaged in research, a business incubator or accelerator, or other not-for-profit entity eligible for capital funding from the Commonwealth of Massachusetts. Institutions that are exclusively health care providers and/or requests for the purchase of equipment associated with standard healthcare delivery would not be eligible for capital funding.
To evaluate applications, an external panel of scientists from academia and industry with expertise in women’s health will review applications in the following categories:
- Qualifications of the Team
- Use of funds and value to the Massachusetts ecosystem
- Proposed plan, including the following: unmet need/market opportunity, data generation and sharing (if applicable), scientist training, and approach to solving a key question in women’s health
Top applicants will be asked to present their proposed project plan to our review panel.
Please view the full list of eligibility requirements and evaluation process.
Learn more about the Women’s Health Initiative
Impact on the Ecosystem
Massachusetts recognizes there has been a lack of development in novel solutions to treat conditions that solely or disproportionately affect women or have a different presentation between genders. This impacts not only patients, but also employers and the healthcare system. The consequences are profound, with women more likely to have adverse drug reactions than men, and the lack of effective therapies results in reduced quality of life. The Massachusetts Life Sciences Center aims to support and incentivize translational project teams developing novel solutions in this area of need.
Connect with us to Learn More
If you have any questions regarding the application process, e-mail: WomensHealth@Masslifesciences.com.